Proteome Sciences plc
("Proteome Sciences")
PRESS RELEASE
US biomarker patent portfolio
The Directors of Proteome Sciences have been made aware of certain speculative and inappropriate comments regarding its US biomarker patent portfolio in light of two recent US court rulings on patent eligibility. We have reviewed the outcomes of the recent U.S. Supreme Court decision on Mayo v. Prometheus and U.S. Court of Appeals for the Federal Circuit decision on Associated Molecular Pathology v. United States Patent and Trademark Office with our US patent attorneys and we conclude that these decisions do not change the status of our issued and pending U.S. applications or impacted our granted U.S. patents which all continue to remain in good standing. The Company continues to fully prosecute and enforce its extensive biomarker patent estate in all territories, including the US to derive maximum value for our shareholders.
For further information please contact:
|
Proteome Sciences plc |
|
|
Christopher Pearce, Chief Executive Officer |
Tel: +44 (0)1932 865065 |
|
Dr. Ian Pike, Chief Operating Officer |
|
|
Dr. Rainer Voegeli |
|
|
James Malthouse, Finance Director |
|
|
Nominated Adviser |
|
|
Cenkos |
|
|
Stephen Keys/Camilla Hume |
Tel: +44 (0)20 7 397 8900 |
|
Public Relations |
|
|
FTI Consulting |
IKON Associates |
|
Ben Atwell / Simon Conway / Mo Noonan |
Adrian Shaw |
|
Tel: +44 (0)20 7269 7116 |
Tel: +44 (0)1483 271291 |
|
Mob : +44 (0)797 9900733 |
This information is provided by RNS